This study is for subjects who have been diagnosed with recurrent or metastatic nasopharyngeal cancer. Subjects are expected to remain in the study for a minimum of 70 months. Drugs are FDA approved and is given through a vein (also called IV or intravenous). The procedures include blood and urine tests, troponin test. Risks include infection, bruising, bleeding, anemia, kidney damage, hearing loss, nausea, vomiting, numbness, pain, rash, blood in urine. You may not receive a benefit from participating in this trial, however, information learned from the trial may help other people in the future.

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

This study will enroll patients and collect blood samples from those who have a newly diagnosed cancer, are going to a procedure for a definitive diagnosis of cancer, or healthy control subjects. These samples that are being collected and banked will be used for future development of blood tests to detect lung cancer in future patients at the earliest stages.

Cancer caregivers in emerging and young adulthood (ages 18-35) are an underresearched and unsupported group of caregivers, and yet they are not uncommon. To address this critical support gap, the goal of this study is to develop and pilot test a caregiving support intervention specifically tailored for emerging and young adults caring for a parent with cancer. This phase of the study is intended to capture feedback on the intervention via focus groups with emerging and young adult caregivers of a parent with cancer.

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The usual approach for patients who are not in a study is to closely watch a patient's condition after surgery and to have regular visits with their doctor to watch for signs of the cancer coming back. Usually, patients do not receive further treatment unless the cancer returns. This study will help determine whether this different approach with durvalumab is better, the same, or worse than the usual approach of observation. Giving durvalumab may help patients live longer and prevent early-stage non-small cell lung cancer from coming back as compared to the usual approach.

This study is for adult patients with head and neck cancer who are at risk of recurrence. The purpose of this study is to evaluate whether the use of Indocyanine Green (ICG) dye allows for better identification of tumor tissue during surgical procedures. Participation will include standard of care visits along with administration of ICG dye and imaging during surgery. Participation in this study will last approximately 6 weeks.

The aim of this supplement study is to learn more about the emotional health and symptom needs of long-term cancer survivors (over 5 years since diagnosis) living with likely incurable disease. Participants in this qualitative substudy will be individuals who are long-term cancer survivors who participated in another study of depression in individuals with likely incurable cancer. We will recruit long-term cancer survivors with likely incurable cancer to participate in one-time, 45- to 60-minute in-depth, semi-structured interviews. We will ask patients about emotional health and symptom burden concerns and elicit attitudes toward digital mental health interventions (DMHI) and preferences for intervention type and delivery. Findings will inform the development of digital mental health interventions tailored to this patient population.

The aim of this supplement study is to learn more about the emotional health and symptom needs of long-term cancer survivors (over 5 years since diagnosis) living with likely incurable disease. Participants in this qualitative substudy will be individuals who are long-term cancer survivors who participated in another study of depression in individuals with likely incurable cancer. We will recruit long-term cancer survivors with likely incurable cancer to participate in one-time, 45- to 60-minute in-depth, semi-structured interviews. We will ask patients about emotional health and symptom burden concerns and elicit attitudes toward digital mental health interventions (DMHI) and preferences for intervention type and delivery. Findings will inform the development of digital mental health interventions tailored to this patient population.